enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Delandistrogene moxeparvovec - Wikipedia

    en.wikipedia.org/wiki/Delandistrogene_moxeparvovec

    Delandistrogene moxeparvovec, sold under the brand name Elevidys, is a recombinant gene therapy used for the treatment of Duchenne muscular dystrophy. [3] It is designed to deliver into the body a gene that leads to production of Elevidys micro-dystrophin that contains selected domains of the dystrophin protein present in normal muscle cells. [3]

  3. Myostatin inhibitor - Wikipedia

    en.wikipedia.org/wiki/Myostatin_inhibitor

    Clinical trials for muscular dystrophy have not proven successful in generating functional improvements compared to placebo. Gains of muscle mass were small to non-existent in this population. [13] Research is ongoing on the potential use of myostatin inhibitors for motor neuron diseases like spinal muscle atrophy and amyotrophic lateral ...

  4. Physical therapy for Duchenne muscular dystrophy - Wikipedia

    en.wikipedia.org/wiki/Physical_therapy_for...

    Devices to help a person with duchenne muscular dystrophy stand are a common treatment approach. [3] Orthotic devices are used (as discussed above) and also specific standing devices such as standing frames, standing wheelchairs, and tables that have a tilt function.

  5. Mom Has 3 Days to Get Son Life-Saving Treatment for Muscular ...

    www.aol.com/mom-3-days-son-life-150759249.html

    “Duchenne muscular dystrophy (DMD) is one of the most severe forms of inherited muscular dystrophies,” the National Library of Medicine says. “Mutations in the dystrophin gene lead to ...

  6. Deflazacort - Wikipedia

    en.wikipedia.org/wiki/Deflazacort

    Although deflazacort was approved by the FDA for use in treatment of Duchenne muscular dystrophy on February 9, 2017, [11] [12] Marathon CEO announced on February 13, 2017, that the launch of deflazacort (Emflaza) would be delayed amidst controversy over the steep price Marathon was asking for the drug in the United States - $89,000 per year ...

  7. Calpainopathy - Wikipedia

    en.wikipedia.org/wiki/Calpainopathy

    Calpainopathy is the most common type of autosomal recessive limb-girdle muscular dystrophy (LGMD). [2] It preferentially affects the muscles of the hip girdle and shoulder girdle. No disease modifying pharmaceuticals have been developed as of 2019, although physical therapy, lifestyle modification, and orthopedic surgery can address symptoms.

  8. LAMA2 related congenital muscular dystrophy - Wikipedia

    en.wikipedia.org/wiki/LAMA2_related_congenital...

    In Qatar, MDC1A constituted 48% of congenital muscular dystrophy subtypes with estimated a point prevalence of 0.8 in 100.000 in a patient cohort from the Gulf and Middle East. [32] Contrastingly, in Australia it constituted 16% of all congenital muscular dystrophy subtypes namely the third most common subtype. [33]

  9. Woman with Muscular Dystrophy Says She Was Dropped ... - AOL

    www.aol.com/lifestyle/woman-muscular-dystrophy...

    Nila Morton was born with a rare form of muscular dystrophy called Ullrich, which requires her to rely on a wheelchair. When it came time to travel home for the holidays this year, she at first ...